|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2011-2-7
|
|
pubmed:abstractText |
Little is known about how the level of disability at the start of treatment with natalizumab affects its efficacy. Objectives: The aim of this study was to investigate the effect of natalizumab on relapses in patients with different levels of baseline disability associated with MS.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1477-0970
|
|
pubmed:author |
pubmed-author:AlonsoAnaA,
pubmed-author:AlvarengaMarcos PapaisMP,
pubmed-author:FernándezOscarO,
pubmed-author:FernándezVictoriaV,
pubmed-author:GuerreroMiguelM,
pubmed-author:López-MadronaJose CarlosJC,
pubmed-author:LeónAntonioA,
pubmed-author:LeyvaLauraL,
pubmed-author:LuqueGloriaG,
pubmed-author:OliverBegoñaB,
pubmed-author:de RamónEnriqueE
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
17
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
192-7
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:21088044-Adult,
pubmed-meshheading:21088044-Antibodies, Monoclonal,
pubmed-meshheading:21088044-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:21088044-Disability Evaluation,
pubmed-meshheading:21088044-Female,
pubmed-meshheading:21088044-Humans,
pubmed-meshheading:21088044-Immunologic Factors,
pubmed-meshheading:21088044-Male,
pubmed-meshheading:21088044-Middle Aged,
pubmed-meshheading:21088044-Multiple Sclerosis, Chronic Progressive,
pubmed-meshheading:21088044-Multiple Sclerosis, Relapsing-Remitting,
pubmed-meshheading:21088044-Predictive Value of Tests,
pubmed-meshheading:21088044-Prospective Studies,
pubmed-meshheading:21088044-Recurrence,
pubmed-meshheading:21088044-Severity of Illness Index,
pubmed-meshheading:21088044-Spain,
pubmed-meshheading:21088044-Time Factors,
pubmed-meshheading:21088044-Treatment Outcome,
pubmed-meshheading:21088044-Young Adult
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
The efficacy of natalizumab in patients with multiple sclerosis according to level of disability: results of an observational study.
|
|
pubmed:affiliation |
Institute of Clinical Neurosciences, Hospital Regional Universitario Carlos Haya, Málaga, Spain. oscar.fernandez.sspa@juntadeandalucia.es
|
|
pubmed:publicationType |
Journal Article
|
